⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502529 | 1.00 | — | — | |
| SCHEMBL2537779 | 0.74 | — | — | |
| SCHEMBL1291153 | 0.74 | — | — | |
| SCHEMBL48555 | 0.67 | — | — | |
| SCHEMBL4490185 | 0.67 | — | — | |
| SCHEMBL20240669 | 0.67 | — | — | |
| SCHEMBL20240560 | 0.67 | — | — | |
| SCHEMBL22076256 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL24204 | 0.64 | — | — | |
| SCHEMBL3343202 | 0.64 | MAN1B1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151257-B | Novel compounds for the treatment of diseases associated with DUX4 expression | 因维戈疗法有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
| EP-4065107-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2022-10-05 | — | — | EP | disclosed |
| CN-115151256-A | Novel compounds for the treatment of diseases associated with DUX expression | FACIO知识产权有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-115151257-A | Novel compounds for the treatment of diseases associated with DUX expression | FACIO知识产权有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021105481-A1 | NOVEL COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021105474-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2018103058-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| EP-1994011-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-7700618-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7598393-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1809607-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1994011-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102059-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2007-09-13 | — | — | WO | disclosed |
| EP-1809607-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | Pfizer, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048754-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER JAPAN INC. (JP) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | KON-I KANA | 2006-05-04 | — | — | US | disclosed |